TEAMING UP for the first-time on the ATP Tour, India's Rohan Bopanna and Ramkumar Ramanathan won the Adelaide International doubles trophy with a hard-fought 7-6 (6), 6-1 win over top seeds Ivan Dodig and Marcelo Melo in Melbourne on Sunday (9).
Bopanna's excellent service returns at crucial times and Ramkumar's all-round game tilted the match in their favour.
In the one hour and 21 minutes contest, the Indians saved all the four break points they faced and broke their rivals twice.
It was Bopanna's 20th ATP doubles title and first for Ramkumar, who was playing only in his second summit clash at this level, having ended a runner-up at the Hall of Fame Tennis Championships in 2018.
"When Ramkumar is serving by your side, you can finish the point early, so that was an advantage," said Bopanna.
Asked how different it was playing with Ramkumar than another compatriot and left-handed Divij Sharan, Bopanan said, "With Divij, we had to create a point, ensure that first volley opportunity is taken while with Ram, the point can be finished early.
"I am surprised not many Indians entered this event. If anyone had landed here, would have entered the field since not many players were there."
Bopanna and Ramkumar will split USD 18700 as prize money and earned 250 ranking points each.
The win would be a huge confidence booster for Ramkumar ahead of the Australian Open Qualifiers, where he will aim to make the singles main draw of a Grand Slam once again.
After saving an early breakpoint, Bopanna and Ramkumar upped their game. In the seventh game, when Melo served at 30-0, Bopanna's unreturnable service on the right of the Dodig and later a crushing forehand winner made it 30-all but the Brazilian eventually held.
Bopanna then saved another breakpoint and converted the deciding deuce point to make it 4-4.
Serving to stay afloat in the set at 5-6, the Indian pair was up 40-30 when Dodig created a winner on Bopanna's serve that whizzed past Ramkumar on his right but the big-serving Coorgi hit an ace to drag it to a tie-breaker.
At 6-6, Bopanna found a service return winner on Melo's serve to earn their second set point and converted with his booming serve.
It was one-way traffic in the second set with the Indians dominating all through.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.